Reconnect Labs AG is a Spin-off of the University of Zürich, with the mission to develop innovative, rapid-acting and sustainable therapies with best-in-class safety, tolerability and user experience profiles for affective disorders, neurodegenerative disorders and chronic pain. Bringing Swiss precision design to the development of psychedelic compounds, with a focus on a patient-centered approach, Reconnect Labs is setting standards for a novel kind of ethical drug development company, embedded in an inclusive stakeholder economy.